AAV Formulation Stability via Magnesium Chloride Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rAAV formulations for gene therapy, such as those used in treating hemophilia A, face stability issues due to the formation of precipitates, which can impact patient safety and the efficacy of the treatment over shelf life, storage, and administration.
Innovation Solution
A stable rAAV vector formulation is developed, comprising sodium chloride, potassium chloride, disodium phosphate, monopotassium phosphate, magnesium chloride, sucrose, and poloxamer 188, with a specific pH range and minimal calcium content, enhancing physical stability and shelf life without the need for added calcium, which was previously believed necessary for stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional rAAV formulations are used, then the gene therapy can be administered, but precipitates form over time which compromises patient safety and product stability
Solution Approach 1:
The patent changes the chemical composition parameters of the formulation by replacing calcium chloride with magnesium chloride and optimizing the concentration of other excipients. This parameter change eliminates precipitate formation while maintaining product stability and safety throughout the shelf life period.
Solution Approach 2:
The patent removes calcium chloride from the formulation composition entirely and replaces it with magnesium chloride. This extraction of the problematic component (calcium) eliminates the root cause of precipitate formation while maintaining the necessary physiological functions.
2Stability of the object's composition
If calcium chloride is added to the formulation, then stability is improved according to conventional belief, but precipitates still form and product quality deteriorates
Solution Approach 1:
The patent converts the harmful effect of calcium chloride (precipitate formation) into a beneficial formulation by replacing it with magnesium chloride. The magnesium chloride provides the necessary stabilizing function without causing precipitate formation, effectively converting a harmful component into a beneficial one.
Solution Approach 2:
The patent uses magnesium chloride as a temporary replacement for calcium chloride during the formulation development phase. This substitution provides immediate relief from precipitate formation issues while the formulation is optimized for long-term stability without requiring calcium.
3Duration of action of stationary object
If the formulation is stored for extended periods, then shelf life requirements are met, but precipitates form and efficacy is reduced
Solution Approach 1:
The patent performs preliminary formulation optimization by incorporating magnesium chloride and other stabilizing excipients before storage begins. This preliminary action prevents precipitate formation from occurring during storage, ensuring product efficacy is maintained throughout the entire shelf life period.
Solution Approach 2:
The patent adds stabilizing excipients and optimizes the formulation composition beforehand to cushion against the harmful effects of storage conditions. This prior cushioning prevents precipitate formation and maintains product quality and efficacy throughout the shelf life period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation improves the appearance, stability, and reduces aggregates, leading to better product quality attributes under freeze/thaw cycles and accelerated stability conditions, ensuring safer and more effective gene therapy delivery.
Implementation Method 1
The composition contains about 150 to about 200 mM, optionally about 172 mM, sodium chloride
Implementation Method 2
The composition contains about 2.5 to about 3.0 mM, optionally about 2.7 mM, potassium chloride; about 0.1 to about 2.0 mM magnesium chloride
Implementation Method 3
The composition contains about 5 to about 10 mM, optionally about 8 mM, disodium phosphate; about 1.0 to about 2.0 mM, optionally about 1.5 mM, monopotassium phosphate; and has a pH of about 7.1 to about 7.5
Implementation Method 4
The composition contains about 0.5% to about 2% (w/v), optionally about 1% (w/v), sucrose; and about 0.01% to about 0.1% (w/v), optionally about 0.05% (w/v), poloxamer 188
Implementation Method 5
The formulation improves the appearance, stability, and reduces aggregates
Implementation Method 6
The formulation improves the appearance, stability, and reduces aggregates, leading to better product quality attributes under freeze/thaw cycles and accelerated stability conditions
Data Source
AI summary
The present invention provides compositions comprising a recombinant AAV and one or more pharmaceutically acceptable excipients. The compositions have improved stability and shelf life as compared to other AAV compositions.